Related Experiment Video
Updated: Dec 5, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
[COVID-19 and venous thromboembolism]
1Pôle d'activité médicochirurgicale cardiovasculaire, nouvel hôpital civil, centre hospitalier régional universitaire de Strasbourg, 67000 Strasbourg, France.
Insights
COVID-19 significantly increases venous thromboembolism (VTE) risk due to endothelial dysfunction and inflammation. Accurate VTE risk stratification is crucial for guiding anticoagulation therapy in patients with COVID-19.
Area of Science:
- Medical Research
- Infectious Diseases
- Cardiology
Background:
- Coronavirus disease 2019 (COVID-19) is linked to a higher occurrence of venous thromboembolism (VTE).
- VTE often presents asymptomatically, negatively impacting patient outcomes.
- Traditional risk factors (e.g., immobility, hypoxemia) and severe COVID-19 features (e.g., obesity, advanced age) contribute to VTE incidence.
Purpose of the Study:
- To investigate the mechanisms underlying the increased VTE risk in COVID-19 patients.
- To highlight the importance of VTE risk stratification for appropriate anticoagulation.
- To discuss the current state of VTE management guidelines in COVID-19.
Main Methods:
- Review of existing literature and observational data on VTE in COVID-19.
- Analysis of pathophysiological mechanisms including endotheliitis and prothrombotic states.
- Discussion of clinical features associated with severe COVID-19 and VTE.
Main Results:
- COVID-19 induces endothelial disease via endotheliitis and a prothrombotic state from inflammation.
- These factors contribute to widespread immunothrombosis in pulmonary vasculature.
- Current VTE risk stratification relies mainly on observational data.
Conclusions:
- Understanding COVID-19's impact on thrombosis is essential for patient care.
- Risk stratification is critical for determining adequate anticoagulation.
- Ongoing randomized controlled trials aim to refine anticoagulant regimens for hospitalized COVID-19 patients.
Abstract:
Coronavirus disease 2019 (COVID-19) is associated with an increased incidence of venous thromboembolism (VTE). Frequently asymptomatic, VTE has a negative impact on patients clinical course. On top of traditional VTE risk factors encountered during COVID-19 such as prolonged bed rest, hypoxemia and intravascular material, main features of patients with severe forms (old age, obesity) explain in part the VTE frequency. In addition, COVID-19 causes an endothelial disease following endotheliitis after the direct invasion of endothelial cells and a prothrombotic state secondary to the strong inflammatory response to infection. Altogether, these mechanisms lead to an extensive immunothrombosis within the pulmonary vasculature. VTE risk stratification to prescribe adequate anticoagulation is an imperious requirement in the COVID-19 treatment. So far, guidelines are mainly based on observational data. Randomized controlled clinical trials are ongoing and will allow to precise the anticoagulant regiment of patients hospitalized for COVID-19.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Return
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
Pulmonary Embolism I: Introduction

